Lyme disease—what is the cost for Scotland?

Joss, A. W. L.; Davidson, M M; Ho-Yen, D. O.; Ludbrook, Anne

doi:10.1016/s0033-3506(03)00067-2

Cited by 24 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If a diagnosis is not made, the patient may go on to develop the late-stage sequelae that are more problematic to manage and debilitating for the patient. Additionally the cost of managing late Lyme disease is estimated to be at least three times greater than that of early Lyme disease in Scotland (Joss et al, 2003). …”

Section: Resultsmentioning

confidence: 99%

Audit of the laboratory diagnosis of Lyme disease in Scotland

Evans

Mavin

Ho-Yen

2005

Journal of Medical Microbiology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Audit of the laboratory diagnosis of Lyme disease in Scotland

Evans

Mavin

Ho-Yen

2005

Journal of Medical Microbiology

View full text Add to dashboard Cite

“…Another study estimated the cost of LB for the Scottish health care system. Although this study was limited to laboratory testing only, the authors estimated a total of GBP 47,000–615,000 for Scotland which seems to be a high financial impact for a country with a relatively low LB incidence [46]. All mentioned investigators used variable assumptions and economical models to assess the general cost of LB making it difficult to directly compare their findings to the results of our study.…”

Section: Discussionmentioning

confidence: 98%

Evaluating Frequency, Diagnostic Quality, and Cost of Lyme Borreliosis Testing in Germany: A Retrospective Model Analysis

Müller

Freitag

Poggensee

et al. 2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Background. Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany. Materials and Methods. We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied. Results. In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26%). 20,986 EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820 EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850€). For Germany, the overall expected cost is estimated at 51,215,105€. However, proficiency testing data questioned test quality and standardization of diagnostic assays used. Conclusion. Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.

show abstract

“…Ticks rarely cause direct losses but as disease vectors (tick borne fever (TBF), louping ill, and tick pyaemia) are important initiators of production losses (Blood and Radostits, 1989;Brodie et al, 1986;Fincham, 1983). Importantly ticks can also communicate Lyme's disease, which can affect humans (Joss et al, 2003). Based on the available published data, it has been assumed that in the autumn, and in the absence of effective control, a mortality level of 1% will be incurred for both TBF and louping ill.…”

Section: The Cost Of Lossesmentioning

confidence: 99%